BSE: SYNGENE - Syngene International Limited

الربحية لمدة ستة أشهر: -20.84%
عائد الأرباح: +0.24%

جدول الترويج Syngene International Limited


عن الشركة Syngene International Limited

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally.

مزيد من التفاصيل
The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

ISIN INE398R01022
Industry Biotechnology
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 0.2417
Дивиденд ао 1.25
Сайт https://www.syngeneintl.com
Цена ао 720.7
تغير السعر يوميا: 0% (701.55)
تغير السعر في الأسبوع: +0.5879% (697.45)
تغير السعر شهريا: +5.34% (666)
تغير السعر خلال 3 أشهر: -14.79% (823.3)
تغير السعر على مدى ستة أشهر: -20.84% (886.25)
تغير السعر سنويا: -6.26% (748.4)
تغير السعر على مدى 3 سنوات: +5.81% (663.05)
تغير السعر على مدى 5 سنوات: +138.83% (293.75)
تغير الأسعار منذ بداية العام: -16.94% (844.65)

الاستهانة

اسم معنى درجة
P/S 8.33 1
P/BV 6.59 1
P/E 55 2
EV/EBITDA 23.43 5
المجموع: 4

كفاءة

اسم معنى درجة
ROA, % 8.29 3
ROE, % 11.98 4
المجموع: 3.33

توزيعات الأرباح

اسم معنى درجة
Div yield, % 0.2417 0.6
DSI 1 10
المجموع: 3.39

واجب

اسم معنى درجة
Debt/EBITDA 0.141 10
المجموع: 10

دافع النمو

اسم معنى درجة
الربحية Revenue, % 67.48 8
الربحية Ebitda, % 30.38 5
الربحية EPS, % 29.09 4
المجموع: 6.2

مشرف مسمى وظيفي قسط سنة الميلاد
Mr. Jonathan Brittan Hunt MD, CEO & Executive Director 84.75M 1969 (56 سنين)
Mr. Sibaji Biswas CFO & Executive Director 34.14M
Krishnan G Head of Investor Relations N/A
Ms. Priyadarshini Mahapatra C.S. Head of Legal, Company Secretary & Compliance Officer 4.72M
Mr. Sandeep Nair Head of Corporate Communications N/A
Mr. Andrew Webster Chief Human Resources Officer N/A
Dr. Dhananjay Patankar Head of Pharmaceutical & Biopharmaceutical Development N/A
Mr. Purushottam Shashikant Singnurkar Head of Formulations Development N/A
Mr. Ajit Manocha Head of IT N/A
Dr. Jayashree Aiyar Ph.D. Head of Discovery Biology N/A

عنوان: India, Bengaluru, Velankani Technology Park - مفتوحة في خرائط جوجل, فتح خرائط ياندكس
موقع إلكتروني: https://www.syngeneintl.com